Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
Details : Through acquisition, Oragenics gained Odyssey’s assets, including drug candidates ONP-002 for mild traumatic brain injury and Niemann-Pick Disease Type C, alongside its nasal delivery device.
Product Name : ONP-002
Product Type : Steroid
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
Details : Oximes-based drug formulation is administered into the upper chamber of the nasal cavity using intranasal device. This helps antidote to cross the blood-brain barrier and spread throughout the brain quickly to reverse the harmful effects of the nerve gas...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Details : Through the agreement, Oragenics acquire Odyssey’s assets including drug candidates, ONP-002 for treating mild traumatic brain injury, and for treating Niemann Pick Disease Type C, as well as Odyssey’s proprietary powder formulation and its nasal del...
Product Name : ONP-002
Product Type : Steroid
Upfront Cash : Undisclosed
May 10, 2023
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroid, also reduces behavioral pathology associated with brain injury symptoms.
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The drug candidate PRV-002 to treat concussion as a novel neurosteroid which can be inhaled through the nose as a powder with pre-clinical data suggesting it can reduce the seriousness of a concussion.
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurostero...
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Erase PTSD
Deal Size : $0.5 million
Deal Type : Funding
Details : These funds will be used to progress the Phase 1 human clinical trials for drug candidate PRV-002 for the treatment of concussion. PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion).
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Undisclosed
October 01, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Erase PTSD
Deal Size : $0.5 million
Deal Type : Funding
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
Details : No severe adverse events were noted as PRV-002 was well-tolerated for all cohorts. No delays were instituted between cohorts. Vital signs, EKG readings, sleep patterns and breathing function were all normal through the entirety of the study.
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Inapplicable
September 28, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion), has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids.
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Odyssey Health Completes Safety Evaluation of Cohort II for Concussion Drug
Details : PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion).In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroi...
Product Name : PRV-002
Product Type : Steroid
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
